报告题目：Insights into diseases of heart, muscle and brain fromhigh resolution structures
报告人：Andrew R. Marks, M.D.
Wu Professor and Chair,
Department of Physiology and Cellular Biophysics
Columbia University College of Physicians & Surgeons
Dr. Andrew R. Marksreceived his undergraduate degree from Amherst College where he was thefirst student in the history of the college to graduate with honors in two subjects (Biology and English),and his M.D. from Harvard Medical School. Following an internship and residency in internal medicineat the Massachusetts General Hospital (MGH), he was a post-doctoral fellow in molecular genetics atHarvard Medical School, and then a clinical cardiology fellow at the MGH. He is board certified in internal medicine and in cardiology. Dr. Marks is Chair and Professor of the Physiology and CellularBiophysics Department at Columbia University. From 2002-2007 Dr. Marks was Editor-in-Chief of theJournal of Clinical Investigation. His honors include: ASCI, AAP, the National Academy of Medicine(2004), American Academy of Arts and Sciences (2005) and the National Academy of Sciences(2005), Doctor of Science HonorisCausa from Amherst College (2009), DocteurHonoriscausa, de
l’Université de Montpellier (2016), the ASCI Stanley J. Korsmeyer Award (2010), the PasarowFoundation Award for Cardiovascular Research (2011) and the Ellison Medical Foundation SeniorScholar in Aging Award (2011), Glorney-Raisbeck Award from NY Academy of Medicine (2016). In2015 Dr. Marks was chosen to present the Ulf von Euler lecture at the Karolinska Institute. Dr. Marks’identification of the mechanism of action of rapamycin’s inhibition of vascular smooth muscleproliferation and migration lead to the development of the first drug-eluting stent (coated withrapamycin) for treatment of coronary artery disease. This substantially reduced the incidence of instentrestenosis. In 2014 Dr. Marks reported the high resolution structure of the mammalian type 1ryanodine receptor/calcium release channel (required for excitation-contraction coupling in skeletalmuscle) which he had cloned and worked on since 1989. His research has contributed newunderstandings of fundamental mechanisms that control muscle contraction, heart function,lymphocyte activation, and cognitive function. He discovered that “leaky” intracellular calcium releasechannels (ryanodine receptors) contribute to heart failure, fatal cardiac arrhythmias, impairedexercise capacity in muscular dystrophy, post-traumatic stress disorder (PTSD) and Alzheimer’s disease. Dr. Marks discovered a new class of small molecules (Rycals), developed in his laboratory,that target leaky ryanodine receptor channels and effectively treat cardiac arrhythmias, heart failure,muscular dystrophy and prevent stress induced cognitive dysfunction and symptoms of Alzheimer’sdisease in pre-clinical studies. Rycals are now in Phase II clinical trials for the treatment of heartfailure and cardiac arrhythmias, and entering clinical trials for the treatment of Duchenne MuscularDystrophy.